No, you're not paranoid. Regulators and legislators really are out to get you.
Fortunately, every cosmetics executive can be thoroughly prepared and armed against the coming onslaught of new safety regulations by reading "The Rose Sheet's" in-depth Special Analysis, 2010 Report On Global Efforts To Advance Cosmetics Regulation.
Just $199! Get this business-critical Special Report HERE.
If FDA approves your product ... is CMS on the same page?
If you think the answer is "yes," you haven't been paying attention. The truth is, the two agencies' agendas are almost entirely separate, and sponsors take either of them for granted at their peril.
But now an exclusive new report, Living in a Bipolar World: Implications of FDA/CMS Collaboration from The RPM Report, untangles the complicated threads of this looming problem and tells you exactly what you need to know to guide your product through the maze.
Just $399! Get this business-critical Special Report HERE.
With the new, abbreviated biosimilar pathway enacted in the Affordable Healthcare Act, is now the time for your company to jump in?
The many layers of this issue are too complex for a simple answer, and you won't find them in mainstream business media. Instead, you'll want to read and understand it all in IN VIVO's exclusive new Special Report, The US Biosimilars Market: The Challenges for Pharmaceutical And Generic Drug Companies.
The Asian marketplace — home of a thousand and one complications, all of them in languages you don't speak — changes daily. And you probably don't have an Asia expert on hand to keep you up to date. But the biggest pharmas do, and their current strategies are on display in an exclusive new report from PharmAsia News.
Flexible Pricing Strategies In Asia: How To Move Beyond Short-term Bottom Lines gets you inside the boardrooms and corner offices of the biggest Asia players. And it's available only from PharmAsia News, the industry's most trusted daily source for critical business intelligence and analysis of the biopharma industry in the Pacific Rim
Now that the shouting about health care reform has died down... what exactly does it mean for you and your company in cold, hard cash?
The answer to that million-dollar question is still being calculated, but you can get a first look at some important estimates in an exclusive new Special Report, Sizing Up Medicare's Donut Hole Discounts: A First Look At How Much Manufacturers Might Owe In Discounts On Drugs In Medicare's Coverage Gap from "The Pink Sheet," the industry’s most trusted source for regulatory and commercialization analysis and intelligence.
Just $95! Get this business-critical Special Report HERE.
